Centessa Pharmaceuticals (CNTA) Change in Acquisitions & Divestments (2023 - 2026)

Centessa Pharmaceuticals (CNTA) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $118.2 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $118.2 million, up 57.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $364.8 million (up 73.56% YoY), and the FY2025 annual result was $321.6 million, up 87.16% from the prior year.
• Change in Acquisitions & Divestments grew to $118.2 million in Q1 2026 per CNTA's latest filing, from $95.6 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $118.2 million in Q1 2026 and troughed at $25.0 million in Q4 2024.
• A 4-year average of $68.2 million and a median of $65.1 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments slumped 51.76% in 2024, then jumped 282.36% in 2025.
• A 4-year view of Change in Acquisitions & Divestments shows it stood at $51.8 million in 2023, then tumbled by 51.76% to $25.0 million in 2024, then jumped by 282.36% to $95.6 million in 2025, then rose by 23.7% to $118.2 million in 2026.
• Business Quant data shows CNTA's Change in Acquisitions & Divestments at $118.2 million in Q1 2026, $95.6 million in Q4 2025, and $107.7 million in Q3 2025.